Editor’s Letter

Welcome to the latest edition of HD Insights, released at the 9th Annual CHDI Huntington’s Disease Therapeutics Conference. HD Insights brings you the latest in HD research, and we are grateful to the HSG, our sponsors, and our more than 1500 subscribers for their continuing support of this mission.

Throughout this issue, we explore the past, present, and future of tetrabenazine, the first FDA-approved treatment for HD. We profile Dr. Kathleen Clarence-Smith, who championed the approval of tetrabenazine by the FDA. We explore Auspex Pharmaceuticals’ lead compound SD-809, a deuterated analogue of tetrabenazine currently in phase III clinical trials. Dr. Pratik Shah, CEO of Auspex, comments on the company’s current projects and describes his hopes for the future. And Dr. Lise Munsie brings you a round-up of current research in HD, including new insights into the mechanisms of tetrabenazine. Also in this issue, we are pleased to feature the highlights of 2013’s HSG Annual Meeting and Clinical Research Symposium, brought to you by Dr. Christina Vaughan. Dr. Hans Johnson describes the use of high-performance computing in the analysis of PREDICT-HD imaging data, and we examine the results of two recently completed randomized controlled drug trials in premanifest HD. We continue to update you on the status of clinical trials, and to give you a glimpse into HD research in Canada.

The HD community is fortunate to benefit from the increasing number of sponsors developing novel therapies for HD. HD Insights relies on the support of these firms to bring their leaders, their compounds, and their research to more than 1500 readers around the globe. If you are interested in becoming a supporter, please contact me at editor@hdinsights.org

We welcome new contributors, suggestions for topics, and suggestions for how we can better serve you. If you or someone you know is interested in contributing to HD Insights, or if you have ideas that you would like to share with 1500 HD researchers and clinicians around the world, please contact me at editor@hdinsights.org . Finally, subscription to HD Insights is always free: simply send us an email at subscribe@hdinsights.org

Dorsey_feat

 

 

 

 

 

 

 

 

Ray Dorsey, MD

Editor, HD INSIGHTSTM

HD DISCLOSURES: DR .DORSEY RECEIVES GRANT SUPPORT FROM LUNDBECK AND PRANA BIOTECHNOLOGY AND CONSULTS FOR AMGEN, LUNDBECK, AND MEDTRONIC.


Editorial Board Members

Ray Dorsey, MD — Editor, University of Rochester

Donald Kennedy, PhD — Stanford University

Nobuyuki Nukina, MD, PhD — Riken Brain Science Institute

Rodrigo Osorio — Agrupacion Chilena de Huntington

Bernard Ravina, MD — Biogen Idec

Ralf Reilmann, MD, PhD — George Huntington Institute

Sarah Tabrizi, MBChB, PhD — University College London

Leslie Thompson, PhD — University of California Irvine

Huntington Study Group

Shari Kinel, JD — HSG Executive Director

Liz McCarthy, BA — HSG Administrative Manager

Contributors

Meredith Achey, BM

Hans Johnson, PhD

Lise Munsie, PhD

Christina Vaughan, MD, MHS

Publication Staff

Meredith Achey, BM — Deputy Editor

Robin Taylor — Production Editor

Martin Holmes — Technical Editor

Dave Kolko — Distribution Specialist


For more information on HD Insights, or to receive a free subscription, please visit us at www.hdinsights.org  or email us at editor@hdinsights.org .